Combination strategies using co-stimulatory receptor agonists are particularly promising in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4), cytokine therapies, and tumor vaccines. The gene discussed is CTLA4; the disease is neoplasm.